Ana Radeljevic
Director/Board Member bij MERRIMACK PHARMACEUTICALS, INC.
Vermogen: 61 384 $ op 31-03-2024
Profiel
Ana Radeljevic is currently the Chief Executive Officer at Adventus Partners since 2016.
She is also an Independent Director at Merrimack Pharmaceuticals, Inc. since 2022 and the Chief Business Officer at ADRx, Inc. since 2021.
Previously, she worked as the Vice President-Financial Planning & Analysis at Revvity, Inc. from 2014 to 2016.
Ms. Radeljevic holds an MBA from Syracuse University and an undergraduate degree from Old Dominion University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-03-2024 | 4 156 ( 0.03% ) | 61 384 $ | 31-03-2024 |
Actieve functies van Ana Radeljevic
| Bedrijven | Functie | Begin |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Director/Board Member | 06-06-2022 |
ADRx, Inc.
 ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01-09-2021 |
Eerdere bekende functies van Ana Radeljevic
| Bedrijven | Functie | Einde |
|---|---|---|
| REVVITY, INC. | Corporate Officer/Principal | 01-01-2016 |
Opleiding van Ana Radeljevic
| Syracuse University | Masters Business Admin |
| Old Dominion University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| REVVITY, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
ADRx, Inc.
ADRx, Inc. Pharmaceuticals: MajorHealth Technology ADRx, Inc. is a biopharmaceutical company. The firm advances drug candidates for Alzhiemer’s disease, systemic amyloidosis and ovarian cancer. The company was founded by Gary Wilcox and David Eisenberg and is headquartered in Thousand Oaks, CA. | Health Technology |
